Stephanie Gaillard

Assistant Professor

20052019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Stephanie Gaillard is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 3 Similar Profiles
Estrogen Receptors Medicine & Life Sciences
Ovarian Neoplasms Medicine & Life Sciences
Orphan Nuclear Receptors Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Carcinoma Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
Peroxisome Proliferator-Activated Receptors Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2005 2019

A phase 1 trial of the oral DNA methyltransferase inhibitor CC-486 and the histone deacetylase inhibitor romidepsin in advanced solid tumors

Gaillard, S., Zahurak, M., Sharma, A., Reiss, K. A., Sartorius-Mergenthaler, S., Downs, M., Anders, N. M., Anders, N., Ahuja, N. & Azad, N., Jan 1 2019, In : Cancer.

Research output: Contribution to journalArticle

Histone Deacetylase Inhibitors
Methyltransferases
Long Interspersed Nucleotide Elements
DNA
Neoplasms

Constitutively active ESR1 mutations in gynecologic malignancies and clinical response to estrogen-receptor directed therapies

Gaillard, S., Andreano, K. J., Gay, L. M., Steiner, M., Jorgensen, M. S., Davidson, B. A., Havrilesky, L. J., Alvarez Secord, A., Valea, F. A., Colon-Otero, G., Zajchowski, D. A., Chang, C. Y., McDonnell, D. P., Berchuck, A. & Elvin, J. A., Jan 1 2019, In : Gynecologic oncology.

Research output: Contribution to journalArticle

Estrogen Receptors
Mutation
Neoplasms
Therapeutics
Aromatase Inhibitors

Identifying markers of immune response in ovarian cancer: does PD-L1 expression meet the mark?

Gaillard, S. & Coleman, R. L., Jul 1 2019, In : Annals of Oncology. 30, 7, p. 1025-1028 4 p., mdz166.

Research output: Contribution to journalReview article

Ovarian Neoplasms
Biomarkers

Loss of ARID1A in tumor cells renders selective vulnerability to combined ionizing radiation and PARP inhibitor therapy

Park, Y., Chui, M. H., Rahmanto, Y. S., Yu, Z. C., Shamanna, R. A., Bellani, M. A., Gaillard, S., Ayhan, A., Viswanathan, A., Seidman, M. M., Franco, S., Leung, A. K. L., Bohr, V. A., Shih, I. M. & Wang, T-L., Sep 15 2019, In : Clinical Cancer Research. 25, 18, p. 5584-5593 10 p.

Research output: Contribution to journalArticle

Ionizing Radiation
DNA Damage
DNA Repair
Radiation
Neoplasms
Endometrial Neoplasms
Early Detection of Cancer
Therapeutics
Disease Resistance
Genome